Cancer Screening in China: PET-CT, Tumor Markers & Early Detection

A comprehensive cancer screening workup — tumor markers, low-dose chest CT, abdominal imaging, mammography or testicular ultrasound, GI endoscopy, and full-body PET-CT — costs USD 4,000 to USD 6,000 at a US executive health program. At a UK private clinic, the equivalent runs GBP 3,000 to GBP 5,000. The same workup at a Tier 3A grade hospital in mainland China is USD 1,200 to USD 1,800, depending on whether PET-CT is included and how many of the standard imaging studies are doubled up.

This is not bargain-bin screening. The PET-CT scanners at Sun Yat-sen Cancer Center, HKU Shenzhen, and Peking University Shenzhen are the same Siemens Biograph and GE Discovery platforms used at MD Anderson and Memorial Sloan Kettering. The radiologists at Sun Yat-sen Cancer Center — one of Asia's leading cancer specialty hospitals — read more oncology imaging per year than most Western centers combined. What you save is geography and labor-market arbitrage, not clinical rigor.

This piece is for patients in two specific situations: those with a strong family history of cancer who want comprehensive baseline screening earlier than standard guidelines suggest, and those over 45 considering a one-time deep workup beyond the standard preventive checkup.

A scope note: SinoCareLink is a medical concierge and consulting service. Clinical procedures are performed by the hospital and its CFDA-licensed physicians. We coordinate appointments and provide bilingual companion support. We do not provide medical services directly.

Who should consider this

You are likely a candidate if any of these apply:

• You have two or more first-degree relatives with cancer of any type, particularly under age 60
• You have a single first-degree relative with a cancer that has hereditary patterns (breast, ovarian, colorectal, pancreatic, gastric, prostate)
• You are over 45 and want a one-time baseline deep workup that goes beyond the standard preventive checkup
• You have persistent unexplained symptoms — unintentional weight loss, persistent fatigue, recurrent low-grade fever — that have been worked up locally without findings
• You are a cancer survivor in surveillance and want a comprehensive interval screen
• You are considering BRCA, Lynch syndrome, or other hereditary cancer testing and want imaging baseline alongside the genetic evaluation

You are not a candidate if:

• You have an active cancer diagnosis — you need a treatment team, not a screening package. PET-CT for staging is a different clinical workflow.
• You have severe renal impairment — PET-CT contrast and dye loads need careful evaluation
• You are pregnant — most cancer imaging is contraindicated
• You are looking for a single tumor-marker blood test to "rule out cancer" — tumor markers do not work that way. See below.

Tumor markers, honestly

A tumor marker is a blood-based protein or molecule that is more often elevated in patients with a specific cancer than in healthy adults. The most commonly used markers in screening packages:

• CEA — colorectal, breast, lung, pancreatic
• AFP — liver (hepatocellular carcinoma)
• CA-19-9 — pancreatic, biliary, gastric
• CA-125 — ovarian
• CA-15-3 — breast
• PSA — prostate
• NSE — small-cell lung
• SCC — squamous cell carcinomas (cervix, head and neck, lung)

Honest assessment: tumor markers have meaningful limitations as screening tools.

• False positives are common. Smokers, heavy drinkers, patients with inflammation or benign conditions (gallstones, fatty liver, prostatitis) often run mildly elevated values. A single elevated CEA on its own does not mean cancer.
• False negatives are also common. Many early-stage cancers do not raise tumor markers above the cutoff. A normal CA-125 does not rule out early ovarian cancer.
• The value is in trends, not snapshots. A tumor marker rising by 50 percent across two annual screens is more informative than a single elevated value, particularly when paired with imaging.

The point of including tumor markers in a screening package is not to diagnose cancer from a blood draw. It is to provide one additional input among many — alongside imaging, clinical exam, and history — that helps the radiologist and physician identify which areas warrant closer attention. Tumor markers without integrated imaging are roughly as useful as a smoke detector without a fire alarm.

What PET-CT actually does

A positron emission tomography combined with computed tomography scan uses a small dose of an injected radioactive tracer (most commonly 18F-fluorodeoxyglucose, FDG) that concentrates in tissues with high metabolic activity. Most cancers are metabolically more active than the surrounding normal tissue, so they show up as bright spots on the scan.

What PET-CT is good at:

• Finding metabolically active cancer anywhere in the body in a single scan. Particularly useful for lymphoma, lung, esophageal, head and neck, colorectal, melanoma.
• Detecting metastases that conventional imaging may miss
• Distinguishing scar tissue from active disease in surveillance after cancer treatment
• Whole-body baseline screening for high-risk patients

What PET-CT is less good at:

• Brain tumors — normal brain tissue is FDG-avid, so brain primaries are often invisible on FDG-PET. Brain MRI is the right tool.
• Slow-growing, low-grade cancers — some prostate cancers, kidney cancers, and well-differentiated tumors are not FDG-avid.
• Very small lesions under about 5 mm — below PET-CT resolution.
• False positives from inflammation, recent infections, recent surgery, brown adipose tissue. A bright spot is not automatically cancer.

PET-CT is a serious tool, not a routine annual screen. Radiation dose is meaningfully higher than a low-dose chest CT (roughly 10 to 20 mSv versus 1 to 2 mSv). Cost at a Chinese Tier 3A hospital runs USD 800 to USD 1,200 depending on the center.

We do not include PET-CT in the standard USD 599 senior premium or USD 699 women's premium. It is an add-on for the specific use cases above.

The full cancer screening package

For high-risk patients we build a workup along these lines, performed at a Tier 3A hospital — typically Sun Yat-sen Cancer Center (Guangzhou) for oncology-heavy cases, or HKU Shenzhen Hospital / Peking University Shenzhen for integrated workups:

Tumor markers (full panel)

• CEA, AFP, CA-19-9, CA-125, CA-15-3, PSA (men), NSE, SCC, CYFRA 21-1

Imaging

• Low-dose chest CT (lung cancer screening)
• Abdominal contrast CT or MRI (liver, pancreas, kidneys, adrenals)
• Mammography + breast ultrasound (women)
• Testicular ultrasound (men, if clinically indicated)
• Thyroid ultrasound
• Transvaginal pelvic ultrasound (women)
• Optional: full-body PET-CT (add-on USD 800 to USD 1,200)
• Optional: brain MRI (add-on USD 400 to USD 600)

Procedures

• Sedated gastroscopy and colonoscopy (USD 400 add-on)
• HPV + TCT cervical screening (women)
• Skin examination by a dermatologist (optional add-on)

Consultations

• Genetic counsellor consultation reviewing family history and recommending whether BRCA / Lynch testing is indicated
• Optional: oncologist consultation reviewing the full workup at the end of the day

Standard supporting workup

• Full cardiovascular panel (ECG, echo, carotid, lipid)
• Full blood and metabolic panel
• Body composition

Total cost depends on which add-ons are included:

• Standard cancer-focused package (without PET-CT): USD 1,200 to USD 1,400
• With PET-CT: USD 1,800 to USD 2,200
• With PET-CT and brain MRI: USD 2,400 to USD 2,800

These are still well under one-third of US executive health program pricing for the equivalent workup.

When Sun Yat-sen Cancer Center is the right choice

Sun Yat-sen Memorial Cancer Center in Guangzhou is one of the leading oncology specialty hospitals in Asia. Annual cancer caseload exceeds 80,000. The radiology and pathology departments are unusually deep — the pathologists in particular see enough rare cases that subtle findings are less likely to be missed.

We route to Sun Yat-sen in these situations:

• Strong family history of multiple cancers suggesting a hereditary cancer syndrome
• Persistent unexplained symptoms where the local workup has been inconclusive
• A patient who is cancer-survivor in long-term surveillance and wants the most experienced radiology read available
• A high-resolution PET-CT read is desired

For integrated screening where cancer is one component among many, HKU Shenzhen Hospital or Peking University Shenzhen Hospital remains the better choice — more general, easier logistics, JCI accreditation.

The 4-day visit, with cancer screening

A typical schedule:

• Day 1: Fly into Hong Kong, Guangzhou, or Shenzhen. Hotel by evening.
• Day 2: If GI endoscopy is included, low-residue diet during the day, laxative prep in the evening. Otherwise, light tourism and acclimatization.
• Day 3: Hospital morning. GI endoscopy first if included, then 3 to 4 hours of imaging and blood work. Visual reports same day. PET-CT, if included, runs over a separate 2-hour window with a 60-minute pre-scan tracer uptake period.
• Day 4: Optional oncologist or hospital physician consultation walking through findings. Genetic counsellor session if relevant. Fly home in the evening.

For complex workups we sometimes split across two hospital days — a more relaxed pace and less fatigue for the patient.

What you actually get

At the end of the visit you take home:

• A printed English-translated comprehensive report summarizing all findings
• Original Chinese reports with formal hospital stamps (often useful for insurance reimbursement)
• Imaging on a USB drive in DICOM format, readable by any radiology software back home
• Pathology slides accessible to your home physician for second-read review (we coordinate slide shipping at cost)
• Recommended follow-up actions organized by priority

Within 5 to 7 business days, any pathology pending at time of departure is forwarded by email — both original Chinese report and English translation.

We strongly recommend that anyone receiving a finding suggestive of cancer — even a borderline tumor marker, even an indeterminate nodule — consult an oncologist in their home country to align on next steps. The Chinese reports are fully usable for this. The pathology vocabulary is internationally standardized.

Honest limitations

A few things we are direct about:

• No screening package finds every cancer. Pancreatic cancer often appears late even with imaging. Some lymphomas present with normal CT and PET. Brain tumors do not show on FDG-PET. The package shifts the odds of early detection significantly — it does not eliminate the risk.
• Findings that look concerning often are not. A 6 mm lung nodule on CT is much more often a benign granuloma than cancer. We help interpret what each finding actually means.
• Action on findings is your home physician's job. SinoCareLink helps coordinate the workup and translates the results. Long-term cancer treatment is a relationship that lives with your home oncologist.
• The screening cost does not include cancer treatment. If something is found, treatment is a separate decision. Some patients choose to be treated in China; most choose to return to their home country with the imaging and pathology in hand.

How to book

Start with the 3-minute online intake. The intake form has dedicated sections for family cancer history, current symptoms, and prior cancer treatment if any. The more detail you provide, the better we can tailor the workup — for some patients PET-CT is essential, for others it adds radiation dose without meaningful clinical benefit.

Within 24 hours you receive a written plan — specific hospital, day-of timetable, total cost, and the specific reasoning for why each component is included or not. Then you decide.

For high-risk patients who have been carrying the question of cancer risk in the back of their mind for years, a single comprehensive workup at a Tier 3A Chinese hospital is one of the more efficient ways to address it. The cost is well under one-third of the equivalent US or UK workup. The clinical rigor is on par. And the bilingual concierge support means the experience is closer to a guided medical visit than a chaotic out-of-country hospital trip.